MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amlaiky, N.
Right arrow Articles by Caron, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amlaiky, N.
Right arrow Articles by Caron, M. G.

Identification of the binding subunit of the D1-dopamine receptor by photoaffinity crosslinking

N Amlaiky, JG Berger, W Chang, RJ McQuade and MG Caron

The D1-dopamine receptor from rat striatum has been successfully identified by photoaffinity crosslinking using a newly synthesized radioiodinated derivative of the selective D1-antagonist SCH-23390. This compound, (R,S)-5-(3'-aminophenyl)-8-chloro-2,3,4,5-tetrahydro-3- methyl-[1H]-3- benzazepin-7-ol(SCH-38548), has been radioiodinated by a chloramine T procedure yielding three radioiodinated products. One of these separated congeners (with Rf = 0.35 on thin layer chromatography; CH2Cl2/MeOH/triethylamine; 82.5:17.5:0.01) binds reversibly to rat striatal membranes with high affinity (KD approximately equal to 200 pM), appropriate stereoselectivity, and D1-dopaminergic specificity. [125I]SCH-38548 can be covalently incorporated into a peptide of Mr approximately equal to 72,000 using the heterobifunctional crosslinking reagent N-succinimidyl-6-(4'-azido-2'-nitrophenylamino)hexanoate. Covalent incorporation of [125I]SCH-38548 into the Mr approximately equal to 72,000 peptide can be blocked by dopaminergic agents with D1- dopaminergic specificity (for agonists: SKF-38393 greater than apomorphine greater than dopamine; for antagonists: SCH-23390 much much greater than, SCH-23388 and cis-flupentixol much much greater than trans-flupentixol). The D1-dopaminergic selectivity and specificity of the labeling were further demonstrated by the fact that other antagonists such as domperidone, ketanserin, phentolamine, and alprenolol did not compete for the covalent labeling of the Mr approximately equal to 72,000 peptide. These results indicate that the ligand-binding subunit of the D1-dopamine receptor resides on peptide distinct from that of the D2-dopamine receptor (Mr = 94,000). This new radioligand should be useful in the molecular characterization of the D1-dopaminergic receptor from various sources.

Volume 31, Issue 2, pp. 129-134, 02/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
C. Fiorentini, C. Busi, E. Gorruso, C. Gotti, P. Spano, and C. Missale
Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization
Mol. Pharmacol., July 1, 2008; 74(1): 59 - 69.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tiberi, S. R. Nash, L. Bertrand, R. J. Lefkowitz, and M. G. Caron
Differential Regulation of Dopamine D1A Receptor Responsiveness by Various G Protein-coupled Receptor Kinases
J. Biol. Chem., February 16, 1996; 271(7): 3771 - 3778.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics